Glimixia-M1 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity without causing significant hypoglycemia. The combination of these two agents provides complementary mechanisms to effectively reduce blood glucose levels in patients inadequately controlled by diet and exercise alone. Glimixia-M1 Tablet PR is formulated for prolonged release, allowing for sustained therapeutic effects and improved patient compliance through once-daily dosing. It is recommended to be used alongside lifestyle modifications including diet and physical activity. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is essential during therapy. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and lactic acidosis in rare cases. This medication should be prescribed and used under medical supervision to optimize diabetes management and minimize potential risks.